NCT02554773View on ClinicalTrials.gov

An Open-label Extension Study of an Investigational Drug, Fitusiran, in Patients With Moderate or Severe Hemophilia A or B

PHASE1/PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

September 18, 2015

Primary Completion Date

March 21, 2023

Study Completion Date

March 21, 2023

Conditions

Hemophilia AHemophilia B

Interventions

DRUG

Fitusiran (SAR439774)

Pharmaceutical form: solution for injection Route of administration : subcutaneous (sc)

Trial Locations (12)

48109

Clinical Trial Site, Ann Arbor

Unknown

Clinical Trial Site, Pittsburgh

Clinical Trial Site, Plovdiv

Clinical Trial Site, Sofia

Clinical Trial Site, Kirov

Clinical Trial Site, Moscow

Clinical Trial Site, Zurich

Clinical Trial Site, Basingstoke

Clinical Trial Site, Glasgow

Clinical Trial Site, Truro

NW3 2QG

Clinical Trial Site, London

SW17 0QT

Clinical Trial Site, London

All Listed Sponsors

lead

Genzyme, a Sanofi Company

INDUSTRY

NCT02554773 - An Open-label Extension Study of an Investigational Drug, Fitusiran, in Patients With Moderate or Severe Hemophilia A or B | Biotech Hunter | Biotech Hunter